Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene

Nature Medicine

Volumn 2, Issue 11, 1996, Pages 1254-1258

  Scrocchi, L A ^a   Brown, T J ^b   MacLusky, N ^b   Brubaker, P L ^c   Auerbach, A B ^d   Joyner, A L ^d   Drucker, D J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEEDING BEHAVIOR; FEMALE; GENE MUTATION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SATIETY;

ANIMALS; BLOOD GLUCOSE; FEMALE; GENE DELETION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE INTOLERANCE; INSULIN; MALE; MICE; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RATS; RECEPTORS, GLUCAGON;

ANIMALIA;

EID: 0029958404     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1196-1254     Document Type: Article

References (36)

1. Creutzfeldt, W. & Ebert, R. New developments in the incretin concept today. Diabetologia 28, 565-573 (1985).
2. Mojsov, S., Weir, G.C. & Habener, J.F. Insulinotropin: Glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79, 616-619 (1987).
3. Kreymann, B., Ghatei, M.A., Williams, G. & Bloom, S.R. Glucagon-like peptide-17-36: A physiological incretin in man. Lancet ii, 1300-1304 (1987).
4. Holst, J.J., Orskov, C., Nielsen, O.V. & Schwartz, T.W. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett. 211, 169-174 (1987).
5. Fehmann, H.-C., Goke, R. & Goke, B. Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent releasing polypeptide. Endocrine Rev. 16, 390-410 (1995).
6. Turton, M.D. et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69-72 (1996).
7. Nauck, M.A. et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91, 301-307 (1993).
8. Nauck, M.A. et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36, 741-744 (1993).
9. Gutniak, M., Orskov, C., Holst, J.J., Ahrén, B. & Efendic, S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326, 1316-1322 (1992).
10. Dupré, J. et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 44, 626-630 (1995).
11. Thorens, B. Expression cloning of the pancreatic B cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc. Natl. Acad. Sci. USA 89, 8641-8645 (1992).
12. Willms, B. et al. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (non-insulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 81, 327-332 (1996).
13. D'Alessio, D.A., Kahn, S.E., Leusner, C.R. & Ensinck, J.W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J. Clin. Invest. 93, 2263-2266 (1994).
14. D'Alessio, D.A., Prigeon, R.L. & Ensinck, J.W. Enterai enhancement of glucose disposition by both insulin-dependent and insulin-independent processes - A physiological role of glucagon-like peptide I. Diabetes 44, 1433-1437 (1995).
15. Toft-Nielsen, M., Madsbad, S. & Holst, J.J. The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45, 552-556 (1996).
16. Thorens, B. et al. Cloning and functional expression of the human islet GLP-1 receptor: Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42, 1678-1682 (1993).
17. Gremlich, S. et al. Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor. Diabetes 44,1202-1208 (1995).
18. Drucker, D.J., Philippe, J., Mojsov, S., Chick, W.L. & Habener, J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. USA 84, 3434-3438 (1987).
19. D'Alessio, D.A. et al. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J. Clin. Invest. 97, 133-138 (1996).
20. Ritzel, R., Orskov, C., Holst, J.J. & Nauck, M.A. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers: Dose-response-relationships. Diabetologia 38, 720-725 (1995).
21. Hoosein, N.M. & Gurd, R.S. Human glucagon-like peptides 1 and 2 activate rat brain adenylate cyclase. FEBS Lett. 178, 83-86 (1984).
22. Kanse, S.M., Kreymann, B., Ghatei, M.A. & Bloom, S.R. Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung. FEBS Lett. 241, 209-212 (1988).
23. Campos, R.V., Lee, Y.C. & Drucker, D.J. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134, 2156-2164 (1994).
24. Wei, Y. & Mojsov, S. Tissue-specific expression of the human receptor for glucagon-like peptide 1: Brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 358, 219-224 (1995).
25. Erickson, J.C., Clegg, K.E. & Palmiter, R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 381, 415-418 (1996).
26. Egan, J.M., Montrose-Rafizadeh, C., Wang, Y., Bernier, M. & Roth, J. Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: One of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135, 2070-2075 (1994).
27. Villanueva-Penacarrillo, M.L., Alcántara, A.I., Clemente, F., Delgado, E. & Valverde, I. Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37, 1163-1166 1994).
28. Hvidberg, A., Nielsen, M.T., Hilsted, J., Orskov, C. & Holst, J.J. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 43, 104-108 (1994).
29. Wheeler, M.B. et al. Functional expression of the rat glucagon-like peptide-I receptor: Evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 133, 57-62 (1993).
30. Tybulewicz, V.L.J., Crawfor, C.E., Jackson, P.K., Bronson, R.T. & Mulligan, R.C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65, 1153-1163 (1991).
31. Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W. & Roder, J.C. Derivation of completely cell culture-derived mice from early passage embryonic stem cells. Proc. Natl. Acad. Sci. USA 90, 8424-8428 (1993).
32. Nagy, A. & Rossant, J. Production of completely ES cell-derived fetuses, in Gene Targeting: A Practical Approach, (ed. Joyner, A.L.) 147-178 (Oxford Univ. Press, Oxford, 1993).
33. Wurst, W. & Joyner, A.L. Production of targeted embryonic stem cell clones. in Gene Targeting: A Practical Approach. (ed. Joyner, A.L.) 33-61 (Oxford Univ. Press, Oxford, 1993).
34. Brubaker, P.L., Lee, Y.C. & Drucker, D.J. Alterations in proglucagon processing and inhibition of proglucagon gene expression in glucagon-SV40 T antigen transgenic mice. J. Biol. Chem. 267, 20728-20733 (1992).
35. 125I- cholecystokinin octapeptide binding in the ventromedial hypothalamic nucleus. Evidence for downmodulation by estrogen. Neuroendocrinology 45, 257-262 (1987).
36. Heinrichs, S.C. et al. Endogenous corticotropin releasing factor modulates feeding induced by neuropeptide Y or a tail-pinch stressor. Peptides 13, 879-884 (1992).